Welcome to our dedicated page for Artelo Biosciences SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artelo Biosciences files regular SEC disclosures that document its clinical development activities, financial position, and material corporate events. For a clinical-stage biopharmaceutical company, these filings reveal how the business allocates capital across research programs, the progress of drug candidates through development stages, and the company's runway for continued operations.
The company's 10-K annual reports and 10-Q quarterly filings provide detailed breakdowns of research and development expenses by program, cash reserves, and clinical trial timelines. These documents explain which drug candidates are in active development, the design of ongoing clinical trials, and the company's strategy for advancing its endocannabinoid-targeted therapeutics toward regulatory approval. For biotech companies, the Management Discussion and Analysis section often contains crucial details about trial enrollment rates, expected data readout timelines, and capital requirements for completing development milestones.
Form 8-K filings from Artelo announce material events including clinical trial results, financing transactions, partnership agreements, and regulatory interactions. These real-time disclosures provide immediate notification when the company announces public equity offerings, completes private placements, or reports significant clinical data. For investors tracking clinical-stage biotech stocks, 8-K filings often contain the most time-sensitive information affecting valuation.
Proxy statements (DEF 14A) reveal executive compensation structures, which for development-stage companies typically include significant stock-based components tied to achieving clinical and regulatory milestones. Form 4 insider transaction filings show when executives and directors buy or sell shares, potentially signaling confidence levels in upcoming clinical readouts or corporate developments.
Our platform provides AI-powered summaries that highlight key disclosures within these technical documents, making it easier to identify changes in cash burn rates, clinical trial progress, and strategic direction without reading through extensive regulatory filings.
Artelo Biosciences filed a Form D reporting a Regulation D exempt offering under Rule 506(b) for a total offering of $9,475,000, all of which has been sold with $0 remaining. The filing identifies the securities as equity, options/warrants and securities to be acquired upon exercise, and lists the first sale date as 2025-08-05. The issuer indicates the offering will not last more than one year.
The notice records 18 investors, states $0 in sales commissions and finders' fees, and reports
Artelo Biosciences reported a quarterly net loss of $3.221 million and a six-month net loss of $5.593 million, while holding $2.066 million in cash and cash equivalents as of June 30, 2025. Current liabilities increased to $5.712 million, producing a working capital deficit of $3.479 million, and management discloses substantial doubt about the Company’s ability to continue as a going concern within one year.
The company completed financings including $900,000 of convertible notes bearing 12% interest (net carrying value $791,000), a June private placement that generated $1.425 million gross ($1.079 million net), an ATM sales agreement for up to $6.5 million, and an expected August PIPE targeting approximately $9.475 million. The Company adopted a Digital Asset Treasury strategy to acquire Solana (SOL); under ASU 2023-08 SOL fair-value changes will flow through net income.
Artelo Biosciences (ARTL) entered into a private placement on 1 Aug 2025, selling 593,252 common shares at $10.20 and 313,435 prefunded warrants at $0.001, each paired with one three-year warrant at $10.20 and one at $50.00. Unit prices of $10.45 (shares) or $10.449 (prefunded) will deliver $9.475 million in gross cash; full cash exercise of the 1.81 million bundled warrants could raise an additional $64.1 million.
Proceeds from the share sale will be used immediately to purchase the cryptocurrency Solana (SOL). Any warrant cash will first fund 12 months of operating requirements; remaining amounts may also be deployed into SOL. The shift establishes a new cryptocurrency treasury strategy and triggers extensive risk disclosures covering SOL price volatility, regulatory uncertainty, Nasdaq listing compliance, Investment Company Act exposure and potential CAMT liabilities.
The offering, exempt under Reg D, is expected to close 5 Aug 2025, with a resale registration due within 15 days. In a separate 7.01 disclosure, the company announced favourable UK MHRA guidance for a first-in-human Phase 1 trial of anxiety-depression candidate ART12.11.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
